Skip to main content

Advertisement

SpringerLink
Log in

Daily Marijuana Use Predicts HIV Seroconversion Among Black Men Who Have Sex with Men and Transgender Women in Atlanta, GA

  • Original Paper
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

We evaluated whether different types of substance use predicted HIV seroconversion among a cohort of 449 Black men who have sex with men (MSM) and transgender women (TGW). A community-based sample was recruited in Atlanta, GA between December 2012 and November 2014. Participants completed a survey and were tested for STIs (Chlamydia and gonorrhoeae using urine samples and rectal swabs) at baseline. HIV testing was conducted at 12-months post enrollment. Multivariable binary logistic regression was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CI) for associations between substance use and HIV seroconversion. By 12-month follow-up, 5.3% (n = 24) of participants seroconverted. In multivariable analyses, daily marijuana use was positively associated with HIV seroconversion (aOR 3.07, 95% CI 1.11–8.48, P = 0.030). HIV incidence was high and daily marijuana use was associated with a more than threefold increased odds of HIV seroconversion among a community-based cohort of Black MSM and TGW.

Resumen

Evaluamos si diferentes tipos de uso de sustancias predijeron la seroconversión del VIH entre una cohorte de 449 hombres que tienen sexo con hombres (HSH) y mujeres transgénero (TGW) de raza negra. Se reclutó una cohorte en la comunidad en Atlanta, GA, entre diciembre de 2012 y noviembre de 2014. Los participantes completaron una encuesta y se les hizo una prueba de infecciones de transmisión sexual (clamidia y gonorrea usando muestras de orina e hisopos rectales) al inicio del estudio. Los participantes completaron una prueba del VIH al final del estudio. Se utilizó la regresión logística binaria multivariable para estimar proporciones de probabilidades ajustadas (aOR) y los intervalos de confianza (CI) del 95% para las asociaciones entre el uso de sustancias y la seroconversión del VIH. A los 12 meses de seguimiento, 5,3% (n = 24) de los participantes se seroconvirtieron. En análisis multivariable, el consumo diario de marijuana se asoció positivamente con la seroconversión del VIH (aOR 3.07, 95% CI 1.11–8.48, P = 0.030). La incidencia del VIH fue elevada y el uso diario de marijuana se asoció con un aumento de más de 3 veces en las probabilidades de seroconversión del VIH entre una cohorte de HSH y TGW de raza negra reclutado por la comunidad.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

The data underlying the results presented in the study are available upon request from Lisa Eaton, lisa.eaton@uconn.edu.

Code Availability

The code used to achieve the results presented in the study is available upon request from Lisa Eaton, lisa.eaton@uconn.edu.

References

  1. Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019. https://doi.org/10.1001/jama.2019.1343.

    Article  PubMed  Google Scholar 

  2. HIV Surveillance Report, 2019. Centers for disease control and prevention; 2021. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-updated-vol-32.pdf.

  3. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas; 2013. hiv surveillance report. 2015; p. 25.

  4. Centers for Disease Control and Prevention. Estimated HIV incidence among adults and adolescents in the United States, 2007–2010. HIV surveillance supplemental report. 2012;17(4). https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-17-4.pdf.

  5. Centers for Disease Control and Prevention. HIV among African American gay and bisexual men [Web]; 2015. https://www.cdc.gov/hiv/group/msm/bmsm.html. Accessed 27 Jan 2022.

  6. Centers for Disease Control and Prevention. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men-five U.S. cities, June 2004–April 2005. MMWR Morb Mortal Wkly Rep. 2005;54(24):597–601.

    Google Scholar 

  7. Harawa N, Greenland S, Bingham T, Johnson D, Cochran S, Cunningham W, et al. Associations of race/ethnicity with HIV prevalence and HIV-related behaviors among young men who have sex with men in 7 urban centers in the United States. J Acquir Immune Defic Syndr. 2004;35(5):526–36.

    Article  PubMed  Google Scholar 

  8. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS ONE. 2011;6(8):e17502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Mitsch A, Singh S, Li J, Balaji A, Linley L, Selik R. Age-associated trends in diagnosis and prevalence of infection with HIV among men who have sex with men—United States, 2008–2016. MMWR Morb Mortal Wkly Rep. 2018;67(37):1025–31.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Matthews DD, Herrick AL, Coulter RW, Friedman MR, Mills TC, Eaton LA, Wilson PA, Stall RD, Team PS. Running backwards Consequences of current HIV incidence rates for the next generation of black MSM in the United States. AIDS Behav. 2016;20(1):7–16. https://doi.org/10.1007/s10461-015-1158-z.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22.

    Article  PubMed  Google Scholar 

  12. Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health. 2019. https://doi.org/10.2105/AJPH.2018.304727.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Poteat T, Reisner SL, Radix A. HIV epidemics among transgender women. Curr Opin HIV AIDS. 2014;9(2):168–73.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr. 2016;72:S210–9.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Schulden JD, Song B, Barros A, Mares-DelGrasso A, Martin CW, Ramirez R, et al. Rapid HIV testing in transgender communities by community-based organizations in three cities. Public Health Rep. 2008;123(Suppl 3):101–14.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rosenberg ES, Grey JA, Sanchez TH, Sullivan PS. Rates of prevalent HIV infection, prevalent diagnoses, and new diagnoses among men who have sex with men in US states, metropolitan statistical areas, and counties, 2012–2013. JMIR Public Health Surveill. 2016;2(1):e22.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Goodreau SM, Rosenberg ES, Jenness SM, Luisi N, Stansfield SE, Millett GA, et al. Sources of racial disparities in HIV prevalence in men who have sex with men in Atlanta, GA, USA: a modelling study. Lancet HIV. 2017;4(7):e311–20.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Sullivan PS, Rosenberg ES, Sanchez TH, Kelley CF, Luisi N, Cooper HL, et al. Explaining racial disparities in HIV incidence in black and white men who have sex with men in Atlanta, GA: a prospective observational cohort study. Ann Epidemiol. 2015;25(6):445–54.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Koblin BA, Mayer KH, Eshleman SH, Wang L, Mannheimer S, del Rio C, et al. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. PLoS ONE. 2013;8(7):e70413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lancki N, Almirol E, Alon L, McNulty M, Schneider JA. Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young Black MSM in Chicago. AIDS. 2018;32(3):383–92.

    Article  PubMed  Google Scholar 

  21. Grov C, Westmoreland D, Morrison C, Carrico AW, Nash D. The crisis we are not talking about: one-in-three annual HIV seroconversions among sexual and gender minorities were persistent methamphetamine users. J Acquir Immune Defic Syndr. 2020;85(3):272–9.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Buchbinder SP, Vittinghoff E, Heagerty PJ, Celum CL, Seage GR 3rd, Judson FN, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2005;39(1):82–9.

    Article  PubMed  Google Scholar 

  23. Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, Mayer K, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20(5):731–9.

    Article  PubMed  Google Scholar 

  24. Sewell J, Miltz A, Lampe FC, Cambiano V, Speakman A, Phillips AN, et al. Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics. Int J Drug Policy. 2017;43:33–43.

    Article  PubMed  Google Scholar 

  25. Boyer CB, Greenberg L, Chutuape K, Walker B, Monte D, Kirk J, et al. Exchange of sex for drugs or money in adolescents and young adults: an examination of sociodemographic factors, HIV-related risk, and community context. J Community Health. 2017;42(1):90–100.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Poteat T, Wirtz AL, Radix A, Borquez A, Silva-Santisteban A, Deutsch MB, et al. HIV risk and preventive interventions in transgender women sex workers. Lancet. 2015;385(9964):274–86.

    Article  PubMed  Google Scholar 

  27. Yu G, Wall MM, Chiasson MA, Hirshfield S. Complex drug use patterns and associated HIV transmission risk behaviors in an Internet sample of U.S. men who have sex with men. Arch Sex Behav. 2015;44(2):421–8.

    Article  PubMed  Google Scholar 

  28. Schneider J, Cornwell B, Jonas A, Lancki N, Behler R, Skaathun B, et al. Network dynamics of HIV risk and prevention in a population-based cohort of young Black men who have sex with men. Netw Sci. 2017;5(3):381–409.

    Article  Google Scholar 

  29. Fulcher JA, Shoptaw S, Makgoeng SB, Elliott J, Ibarrondo FJ, Ragsdale A, et al. Brief report: recent methamphetamine use is associated with increased rectal mucosal inflammatory cytokines, regardless of HIV-1 serostatus. J Acquir Immune Defic Syndr. 2018;78(1):119–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Tapia GR, Glynn TR, Miller C, Manuzak JA, Broedlow CA, McGaugh A, et al. Syndemics and preexposure prophylaxis are independently associated with rectal immune dysregulation in sexual minority men. AIDS. 2021;35(8):1295–300.

    Article  CAS  PubMed  Google Scholar 

  31. Millett GA, Flores SA, Peterson JL, Bakeman R. Explaining disparities in HIV infection among black and white men who have sex with men: a meta-analysis of HIV risk behaviors. AIDS. 2007;21(15):2083–91.

    Article  PubMed  Google Scholar 

  32. Schuler MS, Prince DM, Breslau J, Collins RL. Substance use disparities at the intersection of sexual identity and race/ethnicity: results from the 2015–2018 national survey on drug use and health. LGBT Health. 2020;7(6):283–91.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Philbin MM, Mauro PM, Greene ER, Martins SS. State-level marijuana policies and marijuana use and marijuana use disorder among a nationally representative sample of adults in the United States, 2015–2017: sexual identity and gender matter. Drug Alcohol Depend. 2019;204:107506.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Eaton LA, Kalichman SC, Kalichman MO, Driffin DD, Baldwin R, Zohren L, et al. Randomised controlled trial of a sexual risk reduction intervention for STI prevention among men who have sex with men in the USA. Sex Transm Infect. 2018;94(1):40–5.

    Article  PubMed  Google Scholar 

  35. van der Helm JJ, Hoebe CJ, van Rooijen MS, Brouwers EE, Fennema HS, Thiesbrummel HF, et al. High performance and acceptability of self-collected rectal swabs for diagnosis of chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex Transm Dis. 2009;36(8):493–7.

    Article  PubMed  Google Scholar 

  36. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789–95.

    Article  CAS  PubMed  Google Scholar 

  37. Bradley KA, Kivlahan DR, Zhou XH, Sporleder JL, Epler AJ, McCormick KA, et al. Using alcohol screening results and treatment history to assess the severity of at-risk drinking in veterans affairs primary care patients. Alcohol Clin Exp Res. 2004;28(3):448–55.

    Article  PubMed  Google Scholar 

  38. Dawson DA, Grant BF, Stinson FS, Zhou Y. Effectiveness of the derived alcohol use disorders identification test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. Alcohol Clin Exp Res. 2005;29(5):844–54.

    Article  PubMed  Google Scholar 

  39. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208–17.

    Article  PubMed  Google Scholar 

  40. Bjorgvinsson T, Kertz SJ, Bigda-Peyton JS, McCoy KL, Aderka IM. Psychometric properties of the CES-D-10 in a psychiatric sample. Assessment. 2013;20(4):429–36.

    Article  PubMed  Google Scholar 

  41. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied regression analysis and other multivariable methods. Belmont: Duxbury Press; 1988.

    Google Scholar 

  42. Farrell M, Martin NK, Stockings E, Borquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: challenges and opportunities. Lancet. 2019;394(10209):1652–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Garner BR, Gotham HJ, Knudsen HK, Zulkiewicz BA, Tueller SJ, Berzofsky M, et al. The prevalence and negative impacts of substance use disorders among people with HIV in the United States: a real-time Delphi survey of key stakeholders. AIDS Behav. 2021. https://doi.org/10.1007/s10461-021-03473-9.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Hartzler B, Dombrowski JC, Crane HM, Eron JJ, Geng EH, Christopher Mathews W, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. AIDS Behav. 2017;21(4):1138–48.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Jones J, Grey JA, Purcell DW, Bernstein KT, Sullivan PS, Rosenberg ES. Estimating prevalent diagnoses and rates of new diagnoses of HIV at the state level by age group among men who have sex with men in the United States. Open Forum Infect Dis. 2018;5(6):ofy124.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Williams LD, Ibragimov U, Tempalski B, Stall R, Satcher Johnson A, Wang G, et al. Trends over time in HIV prevalence among people who inject drugs in 89 large US metropolitan statistical areas, 1992–2013. Ann Epidemiol. 2020;45:12–23.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Status of State Medicaid Expansion Decisions: Interactive map [Internet]. Kaiser Family Foundation. 2021. https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-interactive-map/. Accessed 30 Dec 2021.

  48. Baldwin LM, Larson EH, Connell FA, Nordlund D, Cain KC, Cawthon ML, et al. The effect of expanding medicaid prenatal services on birth outcomes. Am J Public Health. 1998;88(11):1623–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Cahill SR, Mayer KH, Boswell SL. The Ryan white HIV/AIDS program in the age of health care reform. Am J Public Health. 2015;105(6):1078–85.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Siegler AJ, Mehta CC, Mouhanna F, Giler RM, Castel A, Pembleton E, et al. Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018. Ann Epidemiol. 2020;45:24–31.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992;19(2):61–77.

    Article  CAS  PubMed  Google Scholar 

  52. Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, et al. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. Clin Infect Dis. 2014;59(7):1020–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Compton WM, Jones CM. Substance use among men who have sex with men. N Engl J Med. 2021;385(4):352–6.

    Article  PubMed  Google Scholar 

  54. Hermanstyne KA, Green HD Jr, Tieu HV, Hucks-Ortiz C, Wilton L, Shoptaw S. The association between condomless anal sex and social support among black men who have sex with men (MSM) in six U.S. cities: a study using data from the HIV prevention trials network BROTHERS study (HPTN 061). AIDS Behav. 2019;23(6):1387–95.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Mimiaga MJ, Reisner SL, Fontaine YM, Bland SE, Driscoll MA, Isenberg D, et al. Walking the line: stimulant use during sex and HIV risk behavior among Black urban MSM. Drug Alcohol Depend. 2010;110(1–2):30–7.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Morgan E, Skaathun B, Michaels S, Young L, Khanna A, Friedman SR, et al. Marijuana use as a sex-drug is associated with HIV risk among black MSM and their network. AIDS Behav. 2016;20(3):600–7.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Morgan E, Khanna AS, Skaathun B, Michaels S, Young L, Duvoisin R, et al. Marijuana use among young black men who have sex with men and the HIV care continuum: findings from the uConnect cohort. Subst Use Misuse. 2016;51(13):1751–9.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Morgan E, Nyaku AN, D’Aquila RT, Schneider JA. Determinants of HIV phylogenetic clustering in chicago among young black men who have sex with men from the uConnect cohort. J Acquir Immune Defic Syndr. 2017;75(3):265–70.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Chen W, Crawford RB, Kaplan BL, Kaminski NE. Modulation of HIVGP120 antigen-specific immune responses in vivo by Delta9-tetrahydrocannabinol. J Neuroimmune Pharmacol. 2015;10(2):344–55.

    Article  PubMed  Google Scholar 

  60. Manuzak JA, Gott TM, Kirkwood JS, Coronado E, Hensley-McBain T, Miller C, et al. Heavy cannabis use associated with reduction in activated and inflammatory immune cell frequencies in antiretroviral therapy-treated human immunodeficiency virus-infected individuals. Clin Infect Dis. 2018;66(12):1872–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Milloy MJ, Marshall B, Kerr T, Richardson L, Hogg R, Guillemi S, et al. High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs. Drug Alcohol Rev. 2015;34(2):135–40.

    Article  PubMed  Google Scholar 

  62. Rom S, Persidsky Y. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol. 2013;8(3):608–20.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Green KM, Musci RJ, Matson PA, Johnson RM, Reboussin BA, Ialongo NS. Developmental patterns of adolescent marijuana and alcohol use and their joint association with sexual risk behavior and outcomes in young adulthood. J Urban Health. 2017;94(1):115–24.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Andrade LF, Carroll KM, Petry NM. Marijuana use is associated with risky sexual behaviors in treatment-seeking polysubstance abusers. Am J Drug Alcohol Abuse. 2013;39(4):266–71.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Dir AL, Gilmore AK, Moreland AD, Davidson TM, Borkman AL, Rheingold AA, et al. What’s the harm? Alcohol and marijuana use and perceived risks of unprotected sex among adolescents and young adults. Addict Behav. 2018;76:281–4.

    Article  PubMed  Google Scholar 

  66. Swartzendruber A, Sales JM, Brown JL, DiClemente RJ, Rose ES. Comparison of substance use typologies as predictors of sexual risk outcomes in African American adolescent females. Arch Sex Behav. 2016;45(1):63–72.

    Article  PubMed  Google Scholar 

  67. Grov C, Westmoreland DA, D’Angelo AB, Pantalone DW. How has HIV pre-exposure prophylaxis (PrEP) changed sex? A review of research in a new era of bio-behavioral HIV prevention. J Sex Res. 2021. https://doi.org/10.1080/00224499.2021.1936440.

    Article  PubMed  Google Scholar 

  68. Delaney KP, Sanchez T, Bowles K, Oraka E, DiNenno E, Sullivan PS. Awareness and use of PrEP appear to be increasing among internet samples of US MSM. In: Conference on retroviruses and opportunistic infections; Boston, Massachusetts; 2016.

  69. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. Clin Infect Dis. 2017;64(2):144–9.

    Article  PubMed  Google Scholar 

  70. Sullivan PS, Giler RM, Mouhanna F, Pembleton ES, Guest JL, Jones J, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Ann Epidemiol. 2018;28(12):833–40.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Sullivan PS, Mouhanna F, Mera R, Pembleton E, Castel AD, Jaggi C, et al. Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. ending the HIV epidemic jurisdictions. Ann Epidemiol. 2020;44:16–30.

    Article  PubMed  Google Scholar 

  72. Misra K, Udeagu C-C. Disparities in awareness of HIV postexposure and preexposure prophylaxis among notified partners of HIV-positive individuals, New York City 2015–2017. JAIDS J Acquir Immune Defic Syndr. 2017;76(2):132–40.

    Article  PubMed  Google Scholar 

  73. Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Harris NS, Johnson AS, Huang Y-LA, Kern D, Fulton P, Smith DK, et al. Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis—United States, 2013–2018. Morb Morta Wkly Rep. 2019;68(48):1117.

    Article  Google Scholar 

  75. Finlayson T, Cha S, Xia M, Trujillo L, Denson D, Prejean J, et al. Changes in HIV preexposure prophylaxis awareness and use among men who have sex with men—20 Urban areas, 2014 and 2017. MMWR Morb Mortal Wkly Rep. 2019;68(27):597–603.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Kanny D, Jeffries WL, Chapin-Bardales J, Denning P, Cha S, Finlayson T, et al. Racial/ethnic disparities in HIV preexposure prophylaxis among men who have sex with men—23 urban areas, 2017. MMWR Morb Mortal Wkly Rep. 2019;68(37):801–6.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Garnett M, Hirsch-Moverman Y, Franks J, Hayes-Larson E, El-Sadr WM, Mannheimer S. Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. AIDS Care. 2018;30(1):9–17.

    Article  PubMed  Google Scholar 

  78. Philbin MM, Mauro PM, Greene ER, LaBossier NJ, Giovenco DP, Martins SS. Medical cannabis laws and medical and non-medical prescription stimulant use among a nationally representative sample of US Adults: Examining the role of sexual identity and gender. Int J Drug Policy. 2020;84:102861.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Moon A, Prentice C. High tech, high finance and high times for U.S. pot industry. London: Reuters; 2017.

    Google Scholar 

  80. Kagia J. Financial analysis and prospects for the cannabis industry. In: Panel presentation; multifaceted effects of the developing cannabis market symposium; February 15; Yale University; New Haven, CT2018.

  81. Hasin DS, Sarvet AL, Cerda M, Keyes KM, Stohl M, Galea S, et al. US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991–1992 to 2012–2013. JAMA Psychiat. 2017;74(6):579–88.

    Article  Google Scholar 

  82. Martins SS, Mauro CM, Santaella-Tenorio J, Kim JH, Cerda M, Keyes KM, et al. State-level medical marijuana laws, marijuana use and perceived availability of marijuana among the general U.S. population. Drug Alcohol Depend. 2016;169:26–32.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Cerda M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, et al. Association between recreational marijuana legalization in the united states and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiat. 2019. https://doi.org/10.1001/jamapsychiatry.2019.3254.

    Article  Google Scholar 

  84. Mauro CM, Newswanger P, Santaella-Tenorio J, Mauro PM, Carliner H, Martins SS. Impact of medical marijuana laws on state-level marijuana use by age and gender, 2004–2013. Prev Sci. 2019;20(2):205–14.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Segura LE, Mauro CM, Levy NS, Khauli N, Philbin MM, Mauro PM, et al. Association of US medical marijuana laws with nonmedical prescription opioid use and prescription opioid use disorder. JAMA Netw Open. 2019;2(7):e197216.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Reboussin BA, Wagoner KG, Sutfin EL, Suerken C, Ross JC, Egan KL, et al. Trends in marijuana edible consumption and perceptions of harm in a cohort of young adults. Drug Alcohol Depend. 2019;205:107660.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Fergusson DM, Boden JM, Horwood LJ. Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. Soc Psychiatry Psychiatr Epidemiol. 2015;50(9):1317–26.

    Article  PubMed  Google Scholar 

  88. Azcarate PM, Zhang AJ, Keyhani S, Steigerwald S, Ishida JH, Cohen BE. Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US population. J Gen Intern Med. 2020;35(7):1979–86.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Keyhani S, Steigerwald S, Ishida J, Vali M, Cerdá M, Hasin D, et al. Risks and benefits of marijuana use: a national survey of U.S. adults. Ann Intern Med. 2018;169(5):282–90.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr. 2004;35(1):38–45.

    Article  PubMed  Google Scholar 

  91. Orsolini L, Chiappini S, Volpe U, Berardis D, Latini R, Papanti GD, et al. Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review. Medicina (Kaunas). 2019;55(9):525.

    Article  Google Scholar 

  92. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat. 2016;73(3):292–7.

    Article  Google Scholar 

  93. Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the national epidemiologic survey on alcohol and related conditions-III. Am J Psychiatry. 2016;173(6):588–99.

    Article  PubMed  PubMed Central  Google Scholar 

  94. White D, Rosenberg ES, Cooper HL, del Rio C, Sanchez TH, Salazar LF, et al. Racial differences in the validity of self-reported drug use among men who have sex with men in Atlanta. GA Drug Alcohol Depend. 2014;138:146–53.

    Article  PubMed  Google Scholar 

  95. Rothman KJ. Epidemiology: an introduction. Oxford: Oxford University Press; 2012.

    Google Scholar 

  96. Adamson SJ, Sellman JD. A prototype screening instrument for cannabis use disorder: the cannabis use disorders identification test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev. 2003;22(3):309–15.

    Article  PubMed  Google Scholar 

  97. Knox J, Reddy V, Lane T, Hasin D, Sandfort T. Substance use and sexual risk behavior among black South African men who have sex with men: the moderating effects of reasons for drinking and safer sex intentions. AIDS Behav. 2017;21(7):2023–32.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Ezell JM, Ferreira MJ, Duncan DT, Schneider JA. The social and sexual networks of black transgender women and black men who have sex with men: results from a representative sample. Transgend Health. 2018;3(1):201–9.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Russell JS, Hickson DA, Timmins L, Duncan DT. Higher rates of low socioeconomic status, marginalization, and stress in black transgender women compared to black cisgender MSM in the MARI Study. Int J Environ Res Public Health. 2021;18(4):2183.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Khalili J, Leung LB, Diamant AL. Finding the perfect doctor: identifying lesbian, gay, bisexual, and transgender-competent physicians. Am J Public Health. 2015;105(6):1114–9.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016;19:21105. https://doi.org/10.7448/IAS.19.7.21105.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Schuler MS, Heins SE, Smart R, Griffin BA, Powell D, Stuart EA, et al. The state of the science in opioid policy research. Drug Alcohol Depend. 2020;214:108137.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The study reported on here were supported by a Grant from the National Institutes of Health (NIH) R01MH094230. Dr. Knox’s effort on this project was supported by NIH Grants K01AA028199, R01DA054553, and R21DA053156. Dr. Duncan was supported in part by grants from the National Institute on Minority Health and Health Disparities (5R01MD013554-04 and 3R01MD013554-04S1), the National Institute on Mental Health (7R01MH112406-05), the National Institute on Drug Abuse (1R01DA054553-01) and the National Heart, Lung and Blood Institute (1R01HL160325-01).Dr. Watson was supported by NIH Grant K01DA047918. Dr Eaton was supported by NIH Grants R01MH094230 and R01DA053168.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Columbia University, 722 West 168th street, New York, 10032, USA

    Justin Knox

  2. HIV Center for Behavioral Studies, New York State Psychiatric Institute, New York, USA

    Justin Knox

  3. Department of Sociomedical Sciences, Columbia University, New York, USA

    Grace Hwang

  4. Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, USA

    Adam W. Carrico

  5. Department of Epidemiology, Columbia University, New York, USA

    Dustin T. Duncan

  6. Department of Human Development and Family Sciences, University of Connecticut, Storrs, USA

    Ryan J. Watson & Lisa A. Eaton

Authors
  1. Justin Knox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grace Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adam W. Carrico
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dustin T. Duncan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryan J. Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lisa A. Eaton
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JK wrote the manuscript. GH served as the lead statistician. GH, AWC, DTD, RJW and LAE assisted with data interpretation and read drafts of the paper. LAE served as the principal investigator for the project.

Corresponding author

Correspondence to Justin Knox.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Consent to Participate

All participants provided written informed consent.

Consent for Publication

The authors affirm that all participant signed informed consent regarding publishing their data.

Ethical Approval

All study protocols received Institutional Review Board approval and the trial was registered in the clinical trials registry, clinicaltrials.gov (NCT02128594).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Knox, J., Hwang, G., Carrico, A.W. et al. Daily Marijuana Use Predicts HIV Seroconversion Among Black Men Who Have Sex with Men and Transgender Women in Atlanta, GA. AIDS Behav 26, 2503–2515 (2022). https://doi.org/10.1007/s10461-022-03598-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-022-03598-5

Keywords

Search

Navigation